Clinical trials: Physical Exercise Condition
- Condition Physical Exercise Condition
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Overweight and Obesity, Health Behavior
Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II
College students are in a newly independent phase of life; many of whom encounter unhealthy dietary decision- making, barriers to physical activity, and poor sleep behaviors.
- Conditions
- Overweight and Obesity, Health Behavior, Sleep Deprivation
- Trial name
- NCT02996864
- Testing
- Healthy Detours App, Fat Secret App
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Diabetes Mellitus
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination.
- Trial name
- NCT04288778
- Testing
- Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
- Where
- 10 sites in India
- Volunteers
- 276 people
- Sponsor
- Johnson & Johnson Private Limited
Diabetes Mellitus
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with…
- Trial name
- NCT00755846
- Testing
- Alogliptin
- Volunteers
- 265 people
- Sponsor
- Takeda
Asthma
A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.
- Trial name
- NCT00812929
- Testing
- GSK2190915
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01323660)
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection…
- Trial name
- NCT03448406
- Testing
- Empagliflozin
- Where
- 108 sites in United States, Australia and 9 more
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.
- Trial name
- NCT02862600
- Testing
- Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Heart Metabolics Limited
Myocardial Perfusion Imaging, Myocardial Ischemia
Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
This study enrolled participants with documented exercise-induced myocardial ischemia in order to evaluate whether ranolazine, when taken prior to exercise, can improve blood flow to the heart (myocardial perfusion), as assessed…
- Trial name
- NCT01221272
- Testing
- Ranolazine, SPECT MPI, Exercise
- Where
- 43 sites in United States, Canada and 6 more
- Volunteers
- 81 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.
- Trial name
- NCT04203797
- Testing
- dupilumab
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes Mellitus
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise…
- Trial name
- NCT02577003
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise…
- Trial name
- NCT05262387
- Testing
- Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy
- Trial name
- NCT01864174
- Testing
- Metformin XR, Metformin IR
- Where
- 156 sites in United States, Canada and 8 more
- Volunteers
- 1,736 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
This study will examine the efficacy of omarigliptin 25 mg once weekly compared to placebo in Japanese patients with T2DM who have inadequate glycemic control on insulin monotherapy in addition to diet and exercise therapy.
- Trial name
- NCT02906709
- Testing
- Omarigliptin, Insulin
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
When using the Breathe Technologies Ventilation System during simulated activities of daily living (ADLs), Subjects with moderate-to-severe chronic obstructive pulmonary Disease (COPD) will be comfortable and report acceptability.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- PRIDE (NCT01355978)
- Testing
- Noninvasive Open Ventilation System
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Breathe Technologies, Inc.
COPD
Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)
To evaluate changes in activity based on the use of portable oxygen concentrators combined with standard of care (SOC) long- term oxygen therapy versus SOC long-term oxygen therapy alone at 12 weeks in patients with COPD who…
- Trial name
- POC-STEP (NCT03513068)
- Testing
- Portable Oxygen Concentrator (POC)
- Where
- 11 sites in United States
- Volunteers
- 108 people
- Sponsor
- ResMed
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo.
- Trial name
- PIONEER 11 (NCT04109547)
- Testing
- Oral semaglutide
- Where
- 66 sites in Algeria, China and 4 more
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
- Trial name
- SCORE (NCT00960076)
- Testing
- Saxagliptin, Metformin XR
- Where
- 35 sites in United States, Colombia and 3 more
- Volunteers
- 282 people
- Sponsor
- AstraZeneca
Heart Failure, Congestive
Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5
The purpose of this study is to determine whether treatment with the OPTIMIZER System is safe and effective in patients with moderate to severe heart failure symptoms.
- Trial name
- NCT00112125
- Testing
- OPTIMIZER System
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Impulse Dynamics